Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS

Stopped Difficulties recruiting participants for the Aviptadil study as there are nowadays very few hospitalized COVID patients. Continuous screening has been carried out but none of the patients met the eligibility criteria for the study.

Conditions

• Covid19
• Corona Virus Infection
• ARDS
• Aviptadil

Interventions

• DRUG: Aviptadil 67μg
• DRUG: Placebo 0.9% NaCl solution

Sponsor

Prof. Dr. Jörg Leuppi